# A Study to Evaluate the Safety, Tolerability and PK of SK-08

> **NCT07021157** · PHASE1 · RECRUITING · sponsor: **Consun Pharmaceutical Group** · enrollment: 48 (estimated)

## Conditions studied

- Chronic Kidney Disease(CKD)

## Interventions

- **DRUG:** SK-08
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07021157
- **Lead sponsor:** Consun Pharmaceutical Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-09
- **Primary completion:** 2025-08-07
- **Final completion:** 2025-08-07
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07021157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07021157, "A Study to Evaluate the Safety, Tolerability and PK of SK-08". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07021157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*